Month: September 2024

Shell plc Second Quarter 2024 Euro and GBP Equivalent Dividend Payments

Written by Customer Service on September 9, 2024. Posted in Dividend Reports And Estimates.

SHELL PLC SECOND QUARTER 2024 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS September 9, 2024 The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the second quarter 2024 interim dividend, which was announced on August 1, 2024 at US$0.344 per ordinary share. Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by September 2, 2024 will be entitled to a dividend of US$0.344, €0.3102 or 26.15p per ordinary share, respectively. Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros at the euro rate per ordinary share shown above. Absent...

Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

Written by Customer Service on September 9, 2024. Posted in Public Companies.

BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with KEYTRUDA® (pembrolizumab) showed promising efficacy data with partial responses in patients with relapsed and refractory advanced melanoma and leiomyosarcoma. BT-001 shows a favorable safety profile with minimal adverse events and no dose-limiting toxicities.Strasbourg, France, and Lund, Sweden, September 9, 2024, 7:00 am CET– Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announce initial promising...

PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence

Written by Customer Service on September 9, 2024. Posted in Public Companies.

PTG-007 cell therapy resulted in clinical remission in some patients for up to 12 years A proportion of patients remained insulin-independent for up to 24 months PTG-007 ready to enter pivotal study Data presented at INNODIA EASD conferenceGdańsk, Poland – 9 September 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces data showing that treatment with its Treg cell therapy, PTG-007, resulted in clinical remission for up to 12 years in patients with type-1 diabetes (T1D). A subset of these patients remained insulin-independent up to 18 to 24 months after treatment. The company will present the data at the INNODIA EASD symposium in Madrid today. “People with type-1 diabetes understand the life-long commitment needed...

SMCP – Update on the proceedings in the relation with a stake of 15.9% of the share capital

Written by Customer Service on September 9, 2024. Posted in Public Companies.

Press release – Paris, September 9th, 2024 Information on the proceedings in relation to the sale of a 15.9% stake of SMCP’s share capital in 2021The Court of Appeal refuses appeals from Dynamic Treasure Group against the English High Court ruling SMCP has been informed that the London Court of Appeal has refused applications for permission to appeal, in particular from Dynamic Treasure Group (DTG) against the English High Court decision of 12 July 2024 ruling that the sale of a stake of 15.9% of SMCP’s shares by European Topsoho S.à r.l. to DTG in 2021 was invalid. There are no further rights of appeal. GLAS SAS (London Branch) has indicated it now intends to take steps to obtain the forced return of this 15.9% stake in Singapore, where the corresponding shares are currently held. ABOUT SMCP SMCP is a global leader in the...

LifeWallet Launches Initiative to Secure New Agreements with Health Plans, Providers, Insurers and Attorneys, Continues Cost Cutting Efforts, and Announces it Secured a Waiver of Acceleration Based on a Negative Going Concern from its Largest Creditor

Written by Customer Service on September 9, 2024. Posted in Public Companies.

CORAL GABLES, Fla., Sept. 08, 2024 (GLOBE NEWSWIRE) — MSP Recovery, Inc. d/b/a LifeWallet (NASDAQ: LIFW) (“LifeWallet,” or the “Company”), a Medicare, Medicaid, commercial, and Secondary Payer reimbursement recovery and technology leader, today announces an initiative to secure new agreements with health plans, providers, insurers and attorneys as it continues to make significant strides in revolutionizing healthcare reimbursement through data-driven solutions and strategic partnerships. This initiative is expected to generate revenue through fees charged on savings from unnecessary Medicare secondary payments. As previously announced, key developments include:Clearinghouse System: In partnership with Palantir Technologies, Inc. (NYSE: PLTR) (“Palantir”), LifeWallet continues to enhance its “Chase to Pay”...

Aura Minerals Inc.: Almas Production Preview – July and August 2024

Written by Customer Service on September 9, 2024. Posted in Public Companies.

ROAD TOWN, British Virgin Islands, Sept. 09, 2024 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA) (B3: AURA33) (OTCQX: ORAAF) (“Aura” or the “Company”) informs its shareholders and the market in general that its Subsidiary, Aura Almas Mineração S.A. (“Almas”), amidst the announced process of issuing its 2nd Debenture and with the objective of ensuring full transparency to investors and debenture holders, has preliminarily disclosed its operational results for the first two months of the third quarter of 2024 (July and August). In July, Almas achieved a total production of 4,723 ounces, and in August, 5,280 ounces. These results not only reflect a stabilized production level but also align with Almas’s previously announced guidance, as well as the stabilization of production following the replacement of the contractor. For comparison...

Aura Minerals Inc.: Notice to the Market

Written by Customer Service on September 9, 2024. Posted in Public Companies.

ROAD TOWN, British Virgin Islands, Sept. 08, 2024 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA) (B3: AURA33) (OTCQX: ORAAF) (“Aura” or the “Company”), informs its shareholders and the market in general that its Subsidiary, Aura Almas Mineração S.A. (“Almas”), held an Extraordinary Shareholders’ General Meeting on this date, which approved the 2nd (second) issuance of simple, non-convertible debentures, secured, in a single series, for public distribution under the automatic registration procedure, by Almas (“Debentures” and “Issuance”, respectively), in a total amount equivalent to five hundred thousand (500,000) debentures, totaling BRL 500,000,000.00 (five hundred million reais). Up to 500,000 (five hundred thousand) Debentures will be issued, with a nominal unit value of BRL 1,000.00 (one thousand reais) on the issue date....

Methanex Corporation Signs Definitive Agreement to Acquire OCI Global’s International Methanol Business for $2.05 Billion

Written by Customer Service on September 9, 2024. Posted in Mergers And Acquisitions.

Except where otherwise noted, all currency amounts are stated in United States dollars.Unique opportunity to acquire world-scale producing methanol assets with access to robust North American natural gas feedstock Aligns with Methanex’s strategic priorities and value-creation strategy Acquisition expected to be immediately accretive to free cash flow per share OCI to hold a 13 percent ownership interest upon closingVANCOUVER, British Columbia, Sept. 08, 2024 (GLOBE NEWSWIRE) — Methanex Corporation (“Methanex” or the “Company”) (TSX:MX) (NASDAQ:MEOH) announced today that it has entered into a definitive agreement to acquire OCI Global’s (“OCI”) international methanol business for $2.05 billion. The transaction includes OCI’s interest in two world-scale methanol facilities in Beaumont, Texas, one of which also produces ammonia....

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

Written by Customer Service on September 9, 2024. Posted in Public Companies.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2024 World Conference on Lung Cancer (“WCLC24”) in San Diego, USA, and the European Society for Medical Oncology (“ESMO”) Congress 2024, taking place in Barcelona, Spain. Results from the FLOWERS study, a prospective, two-arm, randomized, multicenter Phase II clinical trial of osimertinib with or without savolitinib as first-line treatment in EGFRm, MET-aberrant advanced non-small cell lung cancer (“NSCLC”) patients, will be presented at WCLC24. As of May 28, 2024, the median follow-up was 8.2 months. Patients treated with osimertinib plus savolitinib (Cohort 2, N=21)...

MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024

Written by Customer Service on September 8, 2024. Posted in Public Companies.

MacroGenics to host investor call to review key data presented at ESMO on Monday, September 16, 2024, at 8:00 a.m. ET ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced a poster presentation relating to Phase 2 data of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain from September 13-17, 2024. The following poster will be available on Sunday, September 15, 2024: TAMARACK: Randomized Phase 2 trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in...

Month: September 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals